Overview

A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis

Status:
Completed

Trial end date:
2008-01-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the safety, tolerability and activity of escalating multiple doses of SBR759 in patients with chronic kidney disease on hemodialysis.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Ferric Compounds